The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: Baseline characteristics

Nephrology Dialysis Transplantation

Volumn 35, Issue 10, 2020, Pages 1700-1711

  Wheeler, David C ^a   Stefansson, Bergur V ^b   Batiushin, Mikhail ^c   Bilchenko, Oleksandr ^d   Cherney, David Z I ^e,f   Chertow, Glenn M ^g   Douthat, Walter ^h   Dwyer, Jamie P ⁱ   Escudero, Elizabeth ^j   Pecoits Filho, Roberto ^k,l   Furuland, Hans ^m   Górriz, José Luis ⁿ   Greene, Tom ^o   Haller, Hermann ^p   Hou, Fan Fan ^q   Kang, Shin Wook ^r   Isidto, Rey ^s   Khullar, Dinesh ^t   Mark, Patrick B ^u   McMurray, John J V ^u   Kashihara, Naoki ^v   Nowicki, Michal ^w   Persson, Frederik ^x   Correa Rotter, Ricardo ^y   Rossing, Peter ^x,z   Toto, Robert D ^aa   Umanath, Kausik ^ab,ac   van Bui, Pham ^ad   Wittmann, István ^ae   Lindberg, Magnus ^b   David Sjostrom C ^b   Langkilde, Anna Maria ^b   Heerspink, Hiddo J L ^af   more..

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

^c ROSTOV STATE MEDICAL UNIVERSITY   (Russian Federation)

^d KHARKIV MEDICAL ACADEMY OF POSTGRADUATE EDUCATION   (Ukraine)

^e UNIVERSITY HEALTH NETWORK   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h HOSPITAL PRIVADO   (Argentina)

ⁱ VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^j UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^k PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^l ARBOR RESEARCH COLLABORATIVE FOR HEALTH   (United States)

^m UPPSALA UNIVERSITY HOSPITAL   (Sweden)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^o UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^p HANNOVER MEDICAL SCHOOL   (Germany)

^q SOUTHERN MEDICAL UNIVERSITY   (China)

^r Yonsei University College of Medicine   (South Korea)

^s Surgical Clinics and Diagnostics Center   (Philippines)

^t MAX SUPER SPECIALITY HOSPITAL   (India)

^u UNIVERSITY OF GLASGOW   (United Kingdom)

^v KAWASAKI MEDICAL SCHOOL   (Japan)

^w MEDICAL UNIVERSITY OF LODZ   (Poland)

^x STENO DIABETES CENTER   (Denmark)

^y National Institute for Medica Sciences and Nutrition Salvador Zubiran   (Mexico)

^z UNIVERSITY OF COPENHAGEN   (Denmark)

^aa UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^ab HENRY FORD HOSPITAL   (United States)

^ac WAYNE STATE UNIVERSITY   (United States)

^ad Department of Biochemistry and Molecular Biology   (Viet Nam)

^ae UNIVERSITY OF PÉCS   (Hungary)

^af UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

more..

Author keywords

Chronic kidney disease; Dapagliflozin; Randomized controlled clinical trial; Sodium glucose co transporter 2 inhibitor

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; DAPAGLIFLOZIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIURETIC AGENT; ENKEPHALINASE INHIBITOR; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; PHOSPHATE BINDING AGENT; PLACEBO; RENIN INHIBITOR; SULFONYLUREA DERIVATIVE; THIAZIDE DIURETIC AGENT; 2-(3-(4-ETHOXYBENZYL)-4-CHLOROPHENYL)-6-HYDROXYMETHYLTETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ADVERSE OUTCOME; AGED; ALBUMIN TO CREATININE RATIO; ALBUMINURIA; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; HYPERTENSIVE NEPHROPATHY; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY ISCHEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; COMPLICATION; DIABETIC NEPHROPATHY; GLOMERULUS FILTRATION RATE; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS;

AGED; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; GLUCOSIDES; HUMANS; MALE; PROGNOSIS; RENAL INSUFFICIENCY, CHRONIC; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85092553819     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfaa234     Document Type: Article

References (32)

1. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015; 373: 2117–2128
2. Neal B, Perkovic V, Mahaffey KW et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017; 377: 644–657
3. Wiviott SD, Raz I, Bonaca MP et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2019; 380: 347–357
4. Perkovic V, Jardine MJ, Neal B et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019; 380: 2295–2306
5. Heerspink HJ, Perkins BA, Fitchett DH et al. Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications. Circulation 2016; 134: 752–772
6. Thomson SC, Rieg T, Miracle C et al. Acute and chronic effects of SGLT2 blockade on glomerular and tubular function in the early diabetic rat. Am J Physiol Regul Integr Comp Physiol 2012; 302: R75–R83
7. Cherney DZ, Perkins BA, Soleymanlou N et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014; 129: 587–597
8. van Bommel EJM, Muskiet MHA, van Baar MJB et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial. Kidney Int 2020; 97: 202–212
9. Cherney DZI, Dekkers CCJ, Barbour SJ et al. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial. Lancet Diabetes Endocrinol 2020; 8: 582–593
10. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349: 1857–1863
11. Maschio G, Alberti D, Janin G et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 1996; 334: 939–945
12. Hou FF, Zhang X, Zhang GH et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131–140
13. Heerspink HJL, Stefansson BV, Chertow GM et al. Rationale and protocol of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) randomized controlled trial. Nephrol Dial Transplant 2020; 35: 274–282
14. Bakris GL, Agarwal R, Anker SD et al. Design and baseline characteristics of the finerenone in reducing kidney failure and disease progression in diabetic kidney disease trial. Am J Nephrol 2019; 50: 333–344
15. Heerspink HJL, Andress DL, Bakris G et al. Rationale and protocol of the study of diabetic nephropathy with AtRasentan (SONAR) trial: a clinical trial design novel to diabetic nephropathy. Diabetes Obes Metab 2018; 20: 1369–1376
16. Herrington WG, Preiss D, Haynes R et al. The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study. Clin Kidney J 2018; 11: 749–761
17. ClinicalTrials.gov. A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW) (NCT03819153). https://clinicaltrials.gov/ct2/show/ NCT03819153
18. Lv J, Zhang H, Wong MG et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA 2017; 318: 432–442
19. Rauen T, Eitner F, Fitzner C et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med 2015; 373: 2225–2236
20. Barratt J, Rovin B, Diva U et al. Implementing the kidney health initiative surrogate efficacy endpoint in patients with IgA nephropathy (the PROTECT trial). Kidney Int Rep 2019; 4: 1633–1637
21. ClinicalTrials.gov. Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy (Nefigard) (NCT03643965). 2020; https://clinicaltrials.gov/ct2/show/NCT03643965 (accessed July 2020)
22. Heerspink HJL, Parving HH, Andress DL et al. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. Lancet 2019; 393: 1937–1947
23. AstraZeneca. Farxiga Phase III DAPA-CKD Trial Will Be Stopped Early After Overwhelming Efficacy in Patients with Chronic Kidney Disease. 2020; https://www.astrazeneca.com/media-centre/press-releases/2020/farxigaphase-iii-dapa-ckd-trial-will-be-stopped-early-after-overwhelming-efficacyin-patients-with-chronic-kidney-disease.html (accessed July 2020)
24. Lambers Heerspink HJ, Weldegiorgis M, Inker LA et al. Estimated GFR decline as a surrogate end point for kidney failure: a post hoc analysis from the Reduction of End Points in Non-Insulin-Dependent Diabetes with the Angiotensin II Antagonist Losartan (RENAAL) study and Irbesartan Diabetic Nephropathy Trial (IDNT). Am J Kidney Dis 2014; 63: 244–250
25. Jardine MJ, Mahaffey KW, Neal B et al. The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics. Am J Nephrol 2017; 46: 462–472
26. Sharma SG, Bomback AS, Radhakrishnan J et al. The modern spectrum of renal biopsy findings in patients with diabetes. Clin J Am Soc Nephrol 2013; 8: 1718–1724
27. ClinicalTrials.gov. A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy (PROTECT) (NCT03762850). 2020; https://clinicaltrials.gov/ct2/show/NCT03762850 (accessed July 2020)
28. Trachtman H, Nelson P, Adler S et al. DUET: a phase 2 study evaluating the efficacy and safety of sparsentan in patients with FSGS. J Am Soc Nephrol 2018; 29: 2745–2754
29. ClinicalTrials.gov. Study of Sparsentan in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS) (DUPLEX). 2020; https://clinicaltrials.gov/ct2/show/NCT03493685 (accessed July 2020)
30. Lazarus B, Wu A, Shin JI et al. Association of metformin use with risk of lactic acidosis across the range of kidney function: a community-based cohort study. JAMA Intern Med 2018; 178: 903–910
31. Heerspink HJL, Andress DL, Bakris G et al. Baseline characteristics and enrichment results from the SONAR trial. Diabetes Obes Metab 2018; 20: 1829–1835
32. Bayer’s Finerenone Meets Primary Endpoint in Phase III FIDELIO-DKD Renal Outcomes Study in Patients with Chronic Kidney Disease and Type 2 Diabetes. 2020; https://www.drugs.com/clinical_trials/bayer-s-finerenonemeets-primary-endpoint-phase-iii-fidelio-dkd-renal-outcomes-study-patients-18718.html (accessed July 2020)